Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation - Single-center experience and review.
cancer
children
infection
leukemia
parvovirus
transplantation
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
revised:
06
01
2023
received:
15
09
2022
accepted:
17
01
2023
medline:
11
4
2023
pubmed:
8
2
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
Parvovirus B19 (B19V) infection following pediatric hematopoietic cell transplantation (HCT) is a rare complication and available data is scarce. Therefore, we present the experience with B19V Infection in allogeneic pediatric HCT recipients at our transplant center together with a systematic review of the literature. Pediatric HCT patients with Parvovirus B19 infection treated at the University Children's Hospital Münster between 1999 and 2021 were retrospectively identified and clinical data were analyzed. Additionally, a systematic MEDLINE search to identify relevant articles was performed. We identified three out of 445 patients (0.6%) with B19V infection post-transplantation. B19V infection occurred in combination with other complications like Graft-versus-Host disease, additional infections, or autoimmune-mediated hemolysis potentially triggered by B19V. In one patient these complications lead to a fatal outcome. The review of the literature showed considerable morbidity of B19V infection with the potential for life-threatening complications. Most patients were treated by red blood cell transfusion and intravenous immunoglobulins (IVIG) with a high succession rate. Symptomatic B19V infection following HCT remains a rare but potentially challenging complication. A causal antiviral therapy does not exist as well as general recommendations on dosage and duration of IVIG therapy. Despite this, most patients are treated successfully with these measures. Additionally, transmission via blood or stem cell products is also rare and no general recommendations on B19V screenings exist.
Sections du résumé
BACKGROUND
BACKGROUND
Parvovirus B19 (B19V) infection following pediatric hematopoietic cell transplantation (HCT) is a rare complication and available data is scarce. Therefore, we present the experience with B19V Infection in allogeneic pediatric HCT recipients at our transplant center together with a systematic review of the literature.
METHODS
METHODS
Pediatric HCT patients with Parvovirus B19 infection treated at the University Children's Hospital Münster between 1999 and 2021 were retrospectively identified and clinical data were analyzed. Additionally, a systematic MEDLINE search to identify relevant articles was performed.
RESULTS
RESULTS
We identified three out of 445 patients (0.6%) with B19V infection post-transplantation. B19V infection occurred in combination with other complications like Graft-versus-Host disease, additional infections, or autoimmune-mediated hemolysis potentially triggered by B19V. In one patient these complications lead to a fatal outcome. The review of the literature showed considerable morbidity of B19V infection with the potential for life-threatening complications. Most patients were treated by red blood cell transfusion and intravenous immunoglobulins (IVIG) with a high succession rate.
CONCLUSION
CONCLUSIONS
Symptomatic B19V infection following HCT remains a rare but potentially challenging complication. A causal antiviral therapy does not exist as well as general recommendations on dosage and duration of IVIG therapy. Despite this, most patients are treated successfully with these measures. Additionally, transmission via blood or stem cell products is also rare and no general recommendations on B19V screenings exist.
Substances chimiques
Immunoglobulins, Intravenous
0
DNA, Viral
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14028Informations de copyright
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;1:72-73
Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988;25:151-153
Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597
Brown KE, Young NS. Parvoviruses and bone marrow failure. Stem Cells. 1996;14:151-163
Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262:114-117
Broliden K, Tolfvenstam T, Norbeck O, Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260:285-304
Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330:1192-1196
Broliden K. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant. 2001;5:320-330
Barton Rogers B. Parvovirus B19: twenty-five years in perspective. Pediatr Dev Pathol. 1999;2:296-315
Kobayashi S, Maruta A, Yamamoto T, et al. Human parvovirus B19 capsid antigen in granulocytes in parvovirus-B19-induced pancytopenia after bone marrow transplantation. Acta Haematol. 1998;100:195-199
Landry ML. Parvovirus B19. Microbiol Spectr. 2016;4:
Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15:485-505
Florea AV, Ionescu DN, Melhem MF. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med. 2007;131:799-804
Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007;75:373-376
Bültmann BD, Klingel K, Sotlar K, Bock CT, Kandolf R. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch. 2003;442:8-17
Sundin M, Lindblom A, Örvell C, et al. Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation. Biol Blood Marrow Transplant. 2008;14:1172-1179
Bundesärztekammer. Querschnitt-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten Gesamtnovelle 2020. 2020;266-267.
Gama BE, Emmel VE, Oliveira-Silva M, et al. Parvovirus B19 in the context of hematopoietic stem cell transplantation: evaluating cell donors and recipients. Transplant Direct. 2017;3:e217
Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006;43:40-48
Katoh D, Ochi Y, Hiramoto N, et al. Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review. Bone Marrow Transplant. 2020;55:653-656
Atay D, Akcay A, Erbey F, Ozturk G. The impact of alternative donor types on viral infections in pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2018;22.
Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher. 2018;33:108-112
Karastaneva A, Urban C, Lackner H, Schwinger W. Dynamics of graft function measured by DNA-technology in a patient with severe aplastic anemia and repeated stem cell transplantation. Case Rep Med. 2014;2014:576373
Suzuki M, Ito Y, Shimada A, et al. Long-term parvovirus B19 infections with genetic drift after cord blood transplantation complicated by persistent CD4+ lymphocytopenia. J Pediatr Hematol Oncol. 2014;36:e65-68
Öhrmalm L, Gustafson I, Lindblom A, et al. Human parvovirus B19 in pediatric and adult recipients of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2013;48:1366-1367
Larkin T, Li P, Horn B. Parvovirus B19 infection masquerading as relapsed acute lymphoblastic leukaemia following haematopoietic stem cell transplantation. BMJ Case Rep. 2020;13:
Beske F, Modrow S, Sörensen J, et al. Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:89-91
Waruiru C, Slatter MA, Taylor C, et al. Outcome of hematopoietic stem cell transplantation in severe combined immune deficiency with central nervous system viral infection. Pediatr Infect Dis J. 2007;26:129-133
Corbett TJ, Saw H, Popat U, et al. Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant. Bone Marrow Transplant. 1995;16:711-713
Niitsu H, Takatsu H, Miura I, et al. Pure red cell aplasia induced by B19 parvovirus during allogeneic bone marrow transplantation. Rinsho Ketsueki. 1990;31:1566-1571
Rahiala J, Koskenvuo M, Norja P, et al. Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:1308-1312
Plentz A, Würdinger M, Kudlich M, Modrow S. Low-level DNAemia of parvovirus B19 (genotypes 1-3) in adult transplant recipients is not associated with anaemia. J Clin Virol. 2013;58:443-448
Urban C, Lackner H, Müller E, et al. Stem cell transplantation in 6 children with parvovirus B19- induced severe aplastic anaemia or myelodysplastic syndrome. Klin Padiatr. 2011;223:332-334
Schleuning M, Jäger G, Holler E, et al. Human parvovirus B19-associated disease in bone marrow transplantation. Infection. 1999;27:114-117
Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968-977
Tsao EI, Mason MR, Cacciuttolo MA, Bowen SH, Folena-Wasserman G. Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses. Biotechnol Bioeng. 1996;49:130-138
Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187:675-678
Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to Treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3547-3557
Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-935
Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015;125:1986-1994
Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922
Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166
Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21:2113-2121
Plentz A, Hahn J, Knöll A, Holler E, Jilg W, Modrow S. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion. 2005;45:1811-1815
van Hoeven LR, Janssen MP, Lieshout-Krikke RW, Molenaar-de Backer MW. An assessment of the risk, cost-effectiveness, and perceived benefits of anti-parvovirus B19 tested blood products. Transfusion. 2019;59:2352-2360
Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion. 2011;51:1887-1895
Heegaard ED, Laub Petersen B. Parvovirus B19 transmitted by bone marrow. Br J Haematol. 2000;111:659-661
Wasak-Szulkowska E, Grabarczyk P, Rzepecki P. Pure red cell aplasia due to parvovirus B19 infection transmitted probably through hematopoietic stem cell transplantation. Transpl Infect Dis. 2008;10:201-205
Montgomery FU, Cichutek, K, Scriba, PC, Hallek, M. Beschluss der Bundesärztekammer über die erste Fortschreibung der Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen. Deutsches Ärzteblatt Online. 2019;
Lackner H, Sovinz P, Benesch M, et al. The spectrum of parvovirus b19 infection in a pediatric hemato-oncologic ward. Pediatr Infect Dis J. 2011;30:440-442
Rattani N, Matheny C, Eckrich MJ, Madden LM, Quigg TC. Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation. Cancer Rep. 2022;5:e1403